Page 95 - 202001
P. 95
Pharmacogenetic considerations for optimizing tacrolimus 555-560.
dosing in liver and kidney transplant patients[J]. World J [17] 石伟龙,唐惠林,翟所迪. CYP3A4*1G 基因多态性对肾
Gastroenterol,2013,19(48):9156-9173. 移植受者他克莫司给药剂量及血药浓度影响的系统评
[ 6 ] MIANO TA,FLESCH JD,FENG R,et al. Early tacrolim- 价[J].中国临床药理学杂志,2015,31(4):292-296.
us concentrations after lung transplant are predicted by [18] CHO JH,YOON YD,PARK JY,et al. Impact of cyto-
combined clinical and genetic factors and associated with chrome P450 3A and ATP-binding cassette subfamily B
acute kidney injury[J]. Clin Pharmacol Ther,2019.DOI: member 1 polymorphisms on tacrolimus dose-adjusted
10.1002/cpt.1629. trough concentrations among Korean renal transplant re-
[ 7 ] 刘璐,宋沧桑,张阳,等. MDR1 C3435T基因多态性与肾 cipients[J]. Transplant Proc,2012,44(1):109-114.
移植患者他克莫司血药浓度关系的Meta分析[J].中国医 [19] MIURA M,SATOH S,KAGAYA H,et al. Impact of the
院药学杂志,2018,38(23):2440-2446. CYP3A4*1G polymorphism and its combination with
[ 8 ] 中华医学会器官移植学分会.中国肺移植免疫抑制治疗 CYP3A5 genotypes on tacrolimus pharmacokinetics in re-
及排斥反应诊疗规范:2019 版[J].中华移植杂志(电子 nal transplant patients[J]. Pharmacogenomics,2011,12
版),2019,13(2):94-98. (7):977-984.
[ 9 ] CALABRESE DR,FLOREZ R,DEWEY K,et al. Geno- [20] ZHOU LY,ZUO XC,CHEN K,et al. Significant impacts
types associated with tacrolimus pharmacokinetics impact of CYP3A4*1G and CYP3A5*3 genetic polymorphisms
clinical outcomes in lung transplant recipients[J]. Clin on the pharmacokinetics of diltiazem and its main metabo-
Transplant,2018,32(8):e13332. lites in Chinese adult kidney transplant patients[J]. J Clin
[10] GRIFFITH BP,BANDO K,HARDESTY RL,et al. A pro- Pharm Ther,2016,41(3):341-347.
spective randomized trial of FK506 versus cyclosporine [21] HEBERT MF.Contributions of hepatic and intestinal me-
after human pulmonary transplantation[J]. Transplanta- tabolism and P-glycoprotein to cyclosporine and tacrolim-
tion,1994,57(6):848-851. us oral drug delivery[J]. Adv Drug Deliv Rev,1997,27(2/
[11] TREEDE H,GLANVILLE AR,KLEPETKO W,et al. Ta- 3):201-214.
crolimus and cyclosporine have differential effects on the [22] WANG J,ZEEVI A,MCCURRY K,et al. Impact of AB-
risk of development of bronchiolitis obliterans syndrome: CB1(MDR1)haplotypes on tacrolimus dosing in adult
results of a prospective,randomized international trial in lung transplant patients who are CYP3A5 *3/*3 non-ex-
lung transplantation[J]. J Heart Lung Transplant,2012,31 pressors[J]. Transpl Immunol,2006,15(3):235-240.
(8):797-804. [23] LUNDE I,BREMER S,MIDTVEDT K,et al. The influ-
[12] GUETHOFF S,MEISER BM,GROETZNER J,et al. ence of CYP3A,PPARA,and POR genetic variants on the
Ten-year results of a randomized trial comparing tacrolim- pharmacokinetics of tacrolimus and cyclosporine in renal
us versus cyclosporine A in combination with mycopheno- transplant recipients[J]. Eur J Clin Pharmacol,2014,70
late mofetil after heart transplantation[J]. Transplantation, (6):685-693.
2013,95(4):629-634. [24] 徐雯,张晓庆,樊军卫,等.肺移植术后受体CYP3A5和白
[13] BRUNET M,VAN GELDER T,ÅSBERG A,et al. Thera- 介素-10 基因多态性与他克莫司个体化用药的关系[J].
peutic drug monitoring of tacrolimus-personalized thera- 中国药房,2015,26(35):4931-4934.
py:second consensus report[J]. Ther Drug Monit,2019,41 [25] 朱琳,宋洪涛,王庆华,等. CYP3A4*18B 和 CYP3A5*3
(3):261-307. 基因多态性对肾移植患者他克莫司剂量及浓度的影响
[14] LIU F,OU YM,YU AR,et al. Long-term influence of [J].药学学报,2012,47(7):878-883.
CYP3A5,CYP3A4,ABCB1,and NR1I2 polymorphisms [26] DEININGER KM,VU A,PAGE RL,et al. CYP3A phar-
on tacrolimus concentration in Chinese renal transplant re- macogenetics and tacrolimus disposition in adult heart
cipients[J]. Genet Test Mol Biomarkers,2017,21(22): transplant recipients[J]. Clinical Transplantation,2016,30
663-673. (9):1074-1081.
[15] ZHANG JJ,LIU SB,XUE L,et al. The genetic polymor- [27] 卫泽武,王学彬,张文文,等. CYP3A5*3 基因多态性对
phisms of POR*28 and CYP3A5*3 significantly influence 稳定期肾移植受者他克莫司血药浓度及肾功能的影响
the pharmacokinetics of tacrolimus in Chinese renal trans- [J].中国药房,2018,29(2):183-187.
plant recipients[J]. Int J Clin Pharmacol Ther,2015,53 [28] 周红,张菁,伍三兰,等. CYP3A4/5、POR 基因多态性与
(9):728-736. 中国成年心脏移植受者他克莫司血药浓度相关性的研
[16] LUO X,ZHU LJ,CAI NF,et al. Prediction of tacrolimus 究[J].中国药学杂志,2017,52(19):1710-1714.
metabolism and dosage requirements based on CYP3A4 (收稿日期:2019-07-31 修回日期:2019-10-03)
phenotype and CYP3A5*3 genotype in Chinese renal (编辑:邹丽娟)
transplant recipients[J]. Acta Pharmacol Sin,2016,37(4):
中国药房 2020年第31卷第1期 China Pharmacy 2020 Vol. 31 No. 1 ·85 ·